Edition:
India

Sino Biopharmaceutical Ltd (1177.HK)

1177.HK on Hong Kong Stock

16.60HKD
26 Apr 2018
Change (% chg)

HK$-0.18 (-1.07%)
Prev Close
HK$16.78
Open
HK$16.76
Day's High
HK$16.78
Day's Low
HK$16.30
Volume
28,296,460
Avg. Vol
27,694,845
52-wk High
HK$17.46
52-wk Low
HK$6.17

Latest Key Developments (Source: Significant Developments)

Sino Biopharmaceutical Says FY Profit Attributable Up 32.6 Pct
Friday, 23 Mar 2018 

March 23 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::‍RECOMMENDED PAYMENT OF A FINAL DIVIDEND OF HK2 CENTS PER SHARE FOR YEAR​.FY PROFIT ATTRIBUTABLE TO OWNERS OF PARENT WAS RMB2,170.95 MILLION, UP 32.6%.FY REVENUE OF APPROXIMATELY RMB14,819.30 MILLION, AN INCREASE OF APPROXIMATELY 9.4%.  Full Article

Sino Biopharmaceutical Co Announces Acquisition of Sino Biopharm Beijing​ & Super Demand
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::CO TO ACQUIRE SINO BIOPHARM BEIJING​,WHICH OWNS 33.6% OF BEIJING TIDE, BY ISSUING 723.3 MILLION SHARES AT HK$12.73 PER ISSUE SHARE.‍FRANCE INVESTMENT (CHINA 1) GROUP TO SELL 52 PERCENT STAKE IN SUPER DEMAND FOR HK$3.69 BILLION TO CO ​.  Full Article

Sino Biopharmaceutical Product Granted Drug Registration Approval By State FDA Of China​
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::"TENOFOVIR DISOPROXIL FUMARATE TABLET" GRANTED DRUG REGISTRATION APPROVAL BY STATE FOOD AND DRUG ADMINISTRATION OF CHINA​.‍TENOFOVIR DISOPROXIL FUMARATE GRANTED APPROVAL FOR TREATMENT OF CHRONIC HEPATITIS B​.  Full Article

Sino Biopharmaceutical posts 9-month ‍net profit attributable of RMB1.80​ bln
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK> ::9-month ‍revenue RMB11,446.73 million, up 9.5​ percent.‍Declared payment of a third quarterly dividend of HK2 cents per share for three months ended 30 Sept​.9-month net profit attributable to owners RMB1.80​ billion versus RMB1.30 billion.  Full Article

Sino Biopharmaceutical posts HY revenue of about RMB7,482.86 mln
Monday, 21 Aug 2017 

Aug 21 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>:HY revenue was approximately RMB7,482.86 million, an increase of approximately 10.6 percent.Board of directors of company declared payment of a second quarterly dividend of HK2 cents per share.Before accounting for unrealized fair value gains & losses of equity investments & financial assets, HY net profit about RMB1,076.34 million.  Full Article

Sino Biopharmaceutical says qtrly net profit RMB 579 million
Friday, 26 May 2017 

May 26 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::Qtrly revenue was approximately RMB3,863.21 million, an increase of approximately 10.1% over same period last year.Qtrly net profit RMB 579 million versus RMB 427.6 million.Declared payment of a first quarterly dividend of HK1.5 cents per share for three months ended 31 March, 2017.  Full Article

Sino Biopharmaceutical appoints Cheng Cheung Ling as executive director, vice chairlady
Monday, 10 Apr 2017 

Sino Biopharmaceutical Ltd <1177.HK> :Cheng Cheung Ling has been appointed as an executive director, vice chairlady of board.  Full Article

Sino Biopharmaceutical FY profit attributable HK$1.91 bln
Monday, 13 Mar 2017 

Sino Biopharmaceutical Ltd <1177.HK>: FY profit attributable to equity holders HK$1.91 billion, 7.6% higher . FY revenue HK$ 15.83 billion versus HK$14.55 billion .Company recommended payment of a final dividend of HK1.5 cents per share for year ended 31 December, 2016.  Full Article

Sino Biopharmaceutical nine-month net profit HK$1.56 bln
Friday, 18 Nov 2016 

Sino Biopharmaceutical Ltd <1177.HK> : Declared payment of third quarterly dividend of HK1.5 cents per share for three months ended 30 september, 2016 . 9-mnth net profit HK$1.56 billion versus HK$1.39 billion . 9-month revenue HK$12.33 billion compared to HK$11.44 billion a year ago . Pharmaceutical industry in particular also must face operating challenges caused by ongoing reform in public hospitals . Profit in pharmaceutical industry may also be affected as a result of quality consistency assessment of generic drugs ."Expects a general positive development trend in pharmaceutical industry regardless of adjustment pressure in coming quarter".  Full Article

Sino biopharmaceutical enters into a facility agreement
Wednesday, 28 Sep 2016 

Sino Biopharmaceutical Ltd <1177.HK> : Loan facility in an aggregate principal amount of US$300 million . Company, as borrower, entered into a facility agreement with original lenders . Original lenders have agreed to make available to company a dual tranche three-year term loan facility .Amount borrowed under loan facility will be used by company for refinancing of existing loans owed by company.  Full Article

BRIEF-Sino Biopharmaceutical Co Announces Acquisition of Sino Biopharm Beijing​ & Super Demand

* CO TO ACQUIRE SINO BIOPHARM BEIJING​,WHICH OWNS 33.6% OF BEIJING TIDE, BY ISSUING 723.3 MILLION SHARES AT HK$12.73 PER ISSUE SHARE